reason report
recap pipelin track initi data asco
bottom line report financi result provid
pipelin updat larg in-lin expect overal
updat call minor focu
initi phase data two proprietari potenti first-in-
class program antibodi
fusion protein continu view one
compel earli stage pipelin coverag univers clinic
candid either first-in-class only-in-class possibl
best-in-class link link howev given earli stage natur
sever pipelin program current assign valu
advanc stage program includ cabiralizumab anti-
emerg immuno-oncolog program partner
develop combin opdivo
bemarituzumab evalu phase i/iii pivot
fight studi front-lin gastric gastroesophag
junction gej cancer collabor zlab op see multipl
sourc upsid current valuat includ opportun
cabiralizumab beyond pancreat cancer well advanc
earli stage pipelin includ anti-
partner reiter op rais pt
phase ia data expect focu larg
safeti provid initi data antibodi
american societi clinic oncolog manag
indic data updat focu larg safeti patient
phase ia dose escal biomarker-unselect solid
tumor exploratori cohort express recal
last week announc first patient dose dose expans
cohort phase ib studi in-lin prior guidanc
dose expans cohort includ patient breast ovarian
endometri cancer posit express measur
efficaci data cohort expect european societi
preclin present expect
announc present preclin data american
associ cancer research initi phase ia data
dose escal solid tumor expect societi
immunotherapi cancer
catalyst mileston includ initi phase
clinic data esmo
preclin data
initi phase clinic data
multipl dr tgr
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million ep
pleas refer page import disclosur price chart analyst certif
end cash equival
expect end cash equival
expect cash burn vs oper expens
clinic stage oncolog compani proprietari platform facilit acceler
discoveri identif novel therapeut protein platform gener robust
clinic late-preclin stage pipelin leverag asset multipl
strateg collabor valu driver includ cabiralizumab emerg
immuno-oncolog program partner develop combin opdivo
bemarituzumab current evalu phase i/
pivot fight studi front-lin gastric gastroesophag gej cancer
collabor zlab op investor cautiou cabiralizumab follow updat
societi immunotherapi cancer limit visibl futur clinic
updat next develop step medacorp kol spoken remain posit
approach also see multipl sourc upsid current valuat includ
addit opportun cabiralizumab beyond pancreat cancer well advanc
earli stage pipelin includ fusion
partner
price target base blend dcf analysi revenu
multipl analysi assign valu probability-weight royalti cabiralizumab partner
pancreat cancer probabl success also assign valu probability-
weight sale royalti bemarituzumab gastric cancer patient over-express
probabl success opportun cabiralizumab beyond pancreat
cancer earlier stage program repres upsid valuat use discount rate
termin growth rate
pipelin program face clinic regulatori develop risk well commerci
intellectu properti risk also face execut risk financi risk may
addit financ need turn cash flow posit
 mm except per share
total incom expens
bs cf mm
svb leerink estim compani file
chang
oper
invest
financ
svb leerink estim compani file
pipelin upcom event
solid tumor combin opdivo lung scchn
pancreat cancer combin nivolumab
endometri urotheli cancer
phase longer
advanc solid tumor alon combin
